Immunomodulatory Drugs (IMiDs) Increase the Production of IL-2 from Stimulated T Cells by Increasing PKC-θ Activation and Enhancing the DNA-Binding Activity of AP-1 but Not NF-κB, OCT-1, or NF-AT
- 1 October 2005
- journal article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 25 (10), 604-616
- https://doi.org/10.1089/jir.2005.25.604
Abstract
Immunomodulatory drugs (IMiDs) are orally available small molecules that potently inhibit tumor necrosis factor-alpha (TNF-alpha) production by lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (HuPBMCs) but enhance secretion of such cytokines as interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) by stimulated T cells. The mechanism of cytokine regulation by IMiDs has not yet been determined. In the present study, we investigated the effects of one of the IMiDs, CC-4047 (Actimid, Celgene, Warren, NJ), on synthesis of IL-2 protein and mRNA and on the activity and expression of transcription factors. Treatment with CC-4047 enhances the secretion of IL-2 protein and the expression of IL-2 mRNA in a dose-dependent and time-dependent manner. In T cells stimulated with phorbol myristate acetate (PMA)/ionomycin, CC-4047 enhanced the DNA-binding activity of activated protein-1 (AP-1) but not NF-kappaB, Octomer-1 (OCT-1), or NFAT by 2-fold and 4-fold after an incubation time of 1 and 3 h, respectively. Luciferase reporter assays in Jurkat cells showed similar effects on transcription factor activity. Using in vitro kinase activity assays, we also showed that CC-4047 enhances the activity of protein kinase C-theta (PKC-theta) in stimulated T cells. The secreted IL-2 from HuPBMCs was shown to activate natural killer (NK) cells to lyse their target cell line K562. Taken together, our results demonstrate that the IMiDs exert their effects at least in part by activating PKC-theta and acting on AP-1 DNA-binding activity in T cells, resulting in augmented IL-2 synthesis and activation of IL- 2-dependent downstream effectors, such as NK cells.Keywords
This publication has 32 references indexed in Scilit:
- Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN-? and histamine treatment during remission of non-Hodgkin's lymphomaThe Hematology Journal, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Thalidomide: A novel template for anticancer drugsSeminars in Oncology, 2001
- Protein kinase Cθ: a new essential superstar on the T-cell stageImmunology Today, 2000
- Protein Kinase C–Dependent Effects on Leukocyte Migration of ThalidomideThe Journal of Infectious Diseases, 1999
- Constitutive Binding of the Transcription Factor Interleukin-2 (IL-2) Enhancer Binding Factor to the IL-2 PromoterJournal of Biological Chemistry, 1997
- Transcriptional Regulation of the Interleukin-2 Gene in Normal Human Peripheral Blood T CellsJournal of Biological Chemistry, 1996
- Transcription of the Murine Interleukin 5 Gene Is Regulated by Multiple Promoter ElementsPublished by Elsevier BV ,1995
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domainCell, 1993